Clarity Pharmaceuticals (ASX:CU6)
ASX announcement history & article coverage
Transparent by design.
Announcments by Clarity Pharmaceuticals (ASX:CU6) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Ceasing to be a substantial holder
SAR-bisPSMA Presentation - Drug & Device Conference
SECuRE update
Clarity achieves SECuRE Main Group recruitment target and plans registrational Phase III trial
Becoming a substantial holder
CORPORATE GOVERNANCE STATEMENT
Appendix 4G
Annual Report to shareholders
Clarity advances radiopharmaceutical pipeline toward US launch with $178.3 million in liquid assets
Ceasing to be a substantial holder
Becoming a substantial holder
Date of Annual General Meeting 25 November 2026
Preliminary Final Report
Clarity Pharmaceuticals reports FY26 results with increased revenue and loss, advances clinical trials, and strengthens board and manufacturing capacity
Becoming a substantial holder
Ceasing to be a substantial holder
Becoming a substantial holder
Ceasing to be a substantial holder
Bioshares Biotech Summit Presentation
Clarity Pharmaceuticals showcases superior prostate cancer imaging and therapy candidates with strong clinical data and market potential
Becoming a substantial holder
Notification regarding unquoted securities - CU6
SECuRE update
Clarity reports strong early efficacy and safety data for 8 GBq 67Cu-SAR-bisPSMA in prostate cancer SECuRE trial
Ceasing to be a substantial holder
Quarterly Activities/Appendix 4C Cash Flow Report
Clarity Pharmaceuticals reports strong cash, advances clinical trials, and secures manufacturing deal for prostate cancer radiopharmaceuticals
Becoming a substantial holder